Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

July 17, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • COVID herd immunity is probably not possible

WORLD’S FIRST GENOME-EDITED TOMATO

IISER-TVM Research Fellow Vacancy | Biotech | Biochem & Zoology

COVID herd immunity is probably not possible
  • BiotechToday
  • World

COVID herd immunity is probably not possible

bioxone March 29, 2021March 29, 2021

Rohit Bhattacharjee, Amity University, Kolkata

The key to herd immunity is that, whether or not an individual becomes infected, there are too few susceptible hosts around to keep up transmission — individuals who are immunized or have effectively had the disease can’t spread the infection. The vaccines created by Moderna and Pfizer–BioNTech, for instance, are amazingly successful at forestalling symptomatic illness, however, it’s as yet indistinct whether they shield individuals from getting infected, or from spreading the infection to other people. That poses an issue for herd immunity. In most countries, vaccine distribution is stratified by age, with priority given to older people, who are at the very best risk of dying from COVID-19. When and whether there’ll be a vaccine approved for kids, however, remains to be seen. If it’s unattainable to vaccinate children, more adults would wish to be immunized to attain herd immunity.

 Even for a country with high vaccination rates, like Israel, if surrounding countries haven’t done the identical and populations can mix, the potential for new outbreaks remains. Whilst vaccine roll-out plans face distribution and allocation hurdles, new variations of SARS-CoV-2 are growing up that might be more contagious and invulnerable to immunizations. The University of Sao Paulo, Brazil, and her colleagues calculated that over 60% of the population had been infected by June 2020. Consistent with some estimates, that ought to are enough to induce the population to the herd-immunity threshold, but in January, Manaus saw a large resurgence in cases. There’s another problem to manage as immunity grows during a population. Higher rates of immunity can create selective pressure, which might favour variants that will infect folks that are immunized. Counts for herd immunity think about two wellsprings of individual immunity— vaccines and normal contamination. Those that are infected with the SARS-CoV-2 seem to develop some protection from the disease, yet how long that continues going is a matter of question.

Also read:WORLD’S FIRST GENOME-EDITED TOMATO

Source:https://doi.org/10.1038/d41586-021-00728-2

  • Why Do We Age? The Biology Of Ageing Explained
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged COVID-19 Herd Immunity SARS-CoV-2 symptomatic disease VACCINE

2 thoughts on “COVID herd immunity is probably not possible”

  1. Pingback: Hovlinc: a new class of ribozyme - BioXone
  2. Pingback: Neuroplasticity: the kinda flexibility shown by the brain - BioXone

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • Job and Internship
  • Signaling Pathway

IISER-TVM Research Fellow Vacancy | Biotech | Biochem & Zoology

bioxone March 30, 2021

– Shristi Sharma, Team BioXone.in IISER TVM is hiring Biochem/ Biotech/ Zoology candidates for Senior Research Fellow positions. IISER TVM SRF Post. Interested and eligible candidates can check out all of the details on the same below: Name of the Position: Senior Research Fellow (SRF) The number of posts: 01 Name of the Project: Understanding the […]

Related Post

  • BiotechToday
  • World

Food Inhibiting Enzyme That Causes COVID Replication

bioxone December 8, 2020December 8, 2020

Thota Kanishka Rao, Amity University Kolkata Chemical compounds in some food or beverages, like green tea, muscadine grapes, and dark chocolate have been known to bind to and block the function of a protease, in the SARS-CoV-2 virus, according to researchers. Proteases are essential to the health and viability of cells and viruses. On the […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Triple-negative breast cancer and PARP inhibitor to overcome immunosuppressive macrophages

bioxone December 27, 2020December 27, 2020

Parnad Basu, Amity University Kolkata Breast cancer is the second most common cancer in the United States, which happens to women but is also seen in men in some rare cases. Now, triple-negative breast cancer (TNBC) is a specific type of breast cancer where the cancer cells show negative results for estrogen receptor, progesterone receptor, […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Human Papillomavirus: Toxic Agent to Drive Cervical Cancer

BioTech Today July 24, 2021July 23, 2021

Saptaparna Dasgupta, Bennett University According to reported statistics, cervical cancer stands to be the fourth most frequent cancer amongst women all over the world. Human papillomavirus (HPV) acts as the devastating toxic agent that drives cervical cancer.  A study conducted in Tehran University of Medical Sciences involved five different variants of HPV amongst Iranian women […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy